Drugs / SS1(dsFv)-PE38
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01051934 | Dec 2009 → Sep 2011 | adenocarcinoma, non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00024674 | Feb 2001 → ? | neoplasm | INSYS Therapeutics Inc | Withdrawn | No outcome recorded |
| Phase 1 | NCT00024687 | Nov 2000 → ? | neoplasm | INSYS Therapeutics Inc | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01362790 | May 2011 → Aug 2016 | lung adenocarcinoma, mesothelioma, pancreatic neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SS1(dsFv)PE38 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01362790 ↗ |
| Known as | SS1P | “SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin” NCT00024687 ↗ |
| Action | Deplete | “The fused protein retains cell killing activity, but binds only to cells expressing mesothelin.” NCT00024674 ↗ |
| Modality | Protein / enzyme biologic | “The fused protein retains cell killing activity” NCT00024674 ↗ |
| Route | Intravenous | “intravenous SS1(dsFv)-PE38 administered continuously for 10 days” NCT00024674 ↗ |
| Target | MSLN | “Mesothelin binding agent” CHEMBL2109516 ↗ |